Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

Patients who have received Nexavar for unresectable or advanced RCC.

Sorafenib (Nexavar, BAY43-9006)

Bayer Study Director

This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational study for patients with unresectable or advanced RCC under real-life practice conditions. The objective of this study is to assess safety and effectiveness of Nexavar at some limited sites which joined to clinical trial of Nexavar, before available of it in the market. The enrollment period is 2 months, and patients who received Nexavar will be recruited and followed one year since starting Nexavar administration. The data of this study will be integrated into the Nexavar PMS and the data will not be analyzed and reported alone.

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program)

Bayer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program	NCT01412671	Carcinoma, Rena...	Sorafenib (Nexa...	-	Bayer
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program	NCT01412671	Carcinoma, Rena...	Sorafenib (Nexa...	-	Bayer

Spots Global Cancer Trial Database for unresectable or advanced renal cell carcinoma